Study examines off-label molidustat use in anemic cats

Version 2

Molidustat is already familiar to many feline practitioners as the active ingredient in Varenzin-CA1, the first FDA conditionally approved drug for nonregenerative anemia associated with CKD in cats. A newly published retrospective descriptive study now asks a broader question: what happens when clinicians use molidustat in cats with anemia from heterogeneous causes, as often happens in referral and complex-care settings? The answer, at least from this 39-cat single-center cohort, is that hematocrit sometimes improved, but the signal is hard to separate from everything else happening clinically. (fda.gov)

That framing matters because molidustat entered feline practice through a narrow regulatory pathway. FDA conditionally approved Varenzin-CA1 in May 2023 for CKD-associated nonregenerative anemia, allowing marketing while the sponsor continues to collect effectiveness data required for full approval. The labeled regimen is 5 mg/kg orally once daily for up to 28 days, with repeat treatment allowed after at least a seven-day pause. Before molidustat, treatment options largely centered on transfusions, iron supplementation, and off-label erythropoiesis-stimulating agents such as darbepoetin, none of which are specifically approved for this feline indication. (fda.gov)

In the new study, the authors reviewed 39 cats treated in routine practice and found that molidustat was used mostly outside its approved indication. Seventeen cats had a CBC available in the prespecified response window, and 12 met the response criterion of a hematocrit increase of at least 4 percentage points. But that topline number comes with major caveats. Darbepoetin was given at some point during the study period in 22 of 39 cats, and among response-evaluable cats, post-molidustat darbepoetin exposure before the qualifying CBC was common. Other potentially confounding interventions included transfusions, immunosuppressive therapy for immune-mediated anemia, stem cell therapy, and treatment of the underlying disease. The authors’ conclusion is restrained: these data do not establish effectiveness of molidustat for anemia other than CKD-associated anemia. (mdpi.com)

That caution lines up with the broader clinical picture. Review articles and expert education pieces on feline CKD-associated anemia describe the condition as multifactorial, shaped not only by reduced erythropoietin production, but also by inflammation, iron dysregulation, shortened red cell lifespan, and comorbid disease. Shelly Vaden, DVM, PhD, DACVIM, ACVNU, writing in Today’s Veterinary Practice, notes that HIF-prolyl hydroxylase inhibitors such as molidustat may offer advantages over traditional ESAs because they are oral, may produce more physiologic erythropoietin concentrations, and could improve iron homeostasis, though that framework is rooted in CKD-associated anemia rather than mixed-etiology anemia more broadly. (todaysveterinarypractice.com)

The study also lands as the profession continues to sort out where molidustat fits in practice. FDA’s approval materials and public communications emphasize that Varenzin-CA1 is conditionally approved, not fully approved, and that veterinarians should counsel pet parents about possible adverse effects, including vomiting, increased systolic blood pressure, and thromboembolism. That’s especially relevant if clinicians are considering off-label use in cats whose anemia may reflect inflammatory disease, immune-mediated destruction, acute illness, or recent transfusion, where interpreting response can be even more difficult than in CKD alone. (fda.gov)

Why it matters: For veterinary teams, this paper is less a practice-changing endorsement than a useful reality check. It documents that off-label molidustat use is already happening in complicated feline anemia cases, but it also shows how easily retrospective improvement can be overinterpreted when multiple anemia-directed therapies are started, stopped, or overlapped. In practical terms, that supports a careful workup before reaching for molidustat outside labeled CKD use, including attention to regenerative status, iron assessment where feasible, inflammatory or immune-mediated drivers, transfusion timing, and blood pressure monitoring. It also reinforces the need to set expectations with pet parents: a rising hematocrit after treatment doesn’t necessarily prove which intervention made the difference. (mdpi.com)

What to watch: The next step is prospective evidence. The authors call for studies with defined populations, scheduled hematologic monitoring, and tighter control of concurrent erythropoiesis-stimulating treatments. Just as important, clinicians will be watching for additional data on longer-term safety, repeat-course use, and whether any subgroup outside classic CKD-associated nonregenerative anemia shows a reproducible benefit signal strong enough to justify broader adoption. (mdpi.com)